✦ LIBER ✦

Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial

✍ Scribed by Dinesh Khanna; Philip J. Clements; Daniel E. Furst; Joseph H. Korn; Michael Ellman; Naomi Rothfield; Fredrick M. Wigley; Larry W. Moreland; Richard Silver; Youn H. Kim; Virginia D. Steen; Gary S. Firestein; Arthur F. Kavanaugh; Michael Weisman; Maureen D. Mayes; David Collier; Mary E. Csuka; Robert Simms; Peter A. Merkel; Thomas A. Medsger Jr.; Martin E. Sanders; Paul Maranian; James R. Seibold

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 225 KB
Volume: 60
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.24380

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib in active diffuse cutaneous sys

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center

✍ Janet Pope; Donna McBain; Lisa Petrlich; Sharon Watson; Louise Vanderhoek; Faye 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 2 views

## Abstract ## Objective To better understand the feasibility of using imatinib, a tyrosine kinase inhibitor, to treat active diffuse cutaneous systemic sclerosis (dcSSc). ## Methods We performed a 6‐month, randomized, double‐blind, placebo‐controlled, proof‐of‐concept pilot study of imatinib in

Interferon-α does not improve outcome at

Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial

✍ Carol M. Black; Alan J. Silman; Ariane I. Herrick; Christopher P. Denton; Helen 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 1 views

## Objective: To determine whether interferon-alpha (ifnalpha) reduces the severity of skin involvement in early (<3 years) diffuse scleroderma. ## Methods: In a randomized, placebo-controlled, double-blind trial, 35 patients with early scleroderma received subcutaneous injections of either ifnal

Treatment of systemic lupus erythematosu

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial

✍ Kenneth C. Kalunian; John C. Davis Jr.; Joan T. Merrill; Mark C. Totoritis; Davi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

Treatment of rheumatoid arthritis with a

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four–week, multicenter, randomized, double-blind, placebo-controlled trial

✍ Stanley Cohen; Eric Hurd; John Cush; Michael Schiff; Michael E. Weinblatt; Larry 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views

A multicenter, randomized, double-blind,

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease

✍ Arnold E. Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barr 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB 👁 1 views

Abatacept in the treatment of patients w

Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

✍ Philip Mease; Mark C. Genovese; Geoffrey Gladstein; Alan J. Kivitz; Christopher 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 1 views